Effect of immunochemotherapy infusion timing, sequence, and interval on prognosis of advanced esophageal cancer: a retrospective cohort study.

OBJECTIVE

The present study aims to explore the roles of infusion time, administration sequence, and interval of immunochemotherapy (IO) in predicting overall survival (OS) in patients with locally advanced ESCC.

METHODS

This multicenter retrospective study enrolled advanced ESCC who received IO between November 2019 and November 2021. Patients were divided into groups according to the three classifiers (IO infusion time, administration sequence, and infusion interval), and were further analyzed for the roles of these classifiers in predicting the prognosis of the ESCC patients.

RESULTS

A total of 183 eligible patients with locally advanced ESCC were included in this study. Patients who received ≥75% of immunotherapy drug infusions after 12:00 h had better OS compared to those who received <75% of immunotherapy drug infusions after 12:00 h in the 1:1 propensity score matching analysis (HR adjusted : 0.38, 95% CI: 0.17-0.82; P =0.013). Cox proportional hazards regression revealed that ESCC patients with shorter infusion intervals (<3.3 h) had better OS (HR adjusted : 0.34, 95% CI: 0.15-0.76; P =0.008).

CONCLUSION

For patients with ESCC, the OS is significantly better when immunotherapy is administered after 12:00 h. A shorter infusion interval (<3.3 h) on the same-day immunochemotherapy could lead to a better prognosis.